We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 548

Eli Lilly files notice of arbitration in $500m NAFTA dispute against Canada

  • Bereskin & Parr LLP
  • -
  • Canada, Global
  • -
  • September 23 2013

In the past 10 years, there has been a significant increase in the number of Canadian pharmaceutical patents, which have been invalidated by the

Venlafaxine section 8 decision follows “roadmap” set out in previous decisions

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 14 2014

In this decision under section 8 of the Patented Medicines (Notice of Compliance) Regulations ("Regulations"), Justice Zinn of the Federal Court

Punitive damages not available under section 8 of the PM (NOC) Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal which had upheld an order

The year in review: 2014 highlights in Canadian pharmaceutical IP and regulatory news

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 6 2015

The following are highlights of developments in Canadian pharmaceutical intellectual property and regulatory law in 2014

Federal Court grants one of three prohibition applications for VIGAMOX eye drops containing moxifloxacin hydrochloride

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 1 2014

This latest decision from the Federal Court is consistent with a recent trend towards a more literal construction of patent claims. The Court

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Generic companies seek leave to appeal to the Supreme Court of Canada on the “promise of the patent”

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • January 9 2015

On December 23, 2014, Apotex Inc. and Mylan Pharmaceuticals ULC each filed Supreme Court of Canada (SCC) applications for leave to appeal the Federal

What is the threshold for the materiality of an untrue allegation in a patent?

  • Heenan Blaikie LLP
  • -
  • Canada
  • -
  • October 5 2010

In Novo Nordisk Canada Inc. v. Cobalt Pharmaceuticals Inc., 2010 FC 746., Justice Mactavish dismissed an application by Novo Nordisk Canada Inc. (“Novo Nordisk”) under the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a Notice of Compliance to Cobalt Pharmaceuticals Inc. (“Cobalt”) for its generic version of repaglinide, a drug used in the treatment of Type 2 diabetes

Apotex Inc. v. Pfizer Canada Inc., 2011 FCA 236, latanoprost

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 22 2011

In this decision under the Patented Medicines (Notice of Compliance) Regulations, the Federal Court of Appeal set aside the applications judge’s order prohibiting the issuance of a NOC to Apotex for the medicine latanoprost

Costs awarded on substantial indemnity basis for summary judgment motion

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 28 2013

Abbott and Takeda had previously been successful in a motion for partial summary judgment dismissing Apotex’ claims for disgorgment of profits based